• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»aesthetic dermatology

Why the Veradermics hair loss trial is bigger than another aesthetics readout

By Pallavi Madhiraju on April 27, 2026   Pharma & Biotech  

Why the Veradermics hair loss trial is bigger than another aesthetics readout

Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.

How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem

By Pallavi Madhiraju on April 16, 2026   Pharma & Biotech  

How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem

Galderma has launched Regenerating Skin Nectar with TriHex+. Read why this matters for peri-procedural skincare, clinics, and regenerative aesthetics.

How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine

By Pallavi Madhiraju on February 12, 2026   Pharma & Biotech  

How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine

Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.

Cynosure Lutronic sets stage for global Mosaic 3D rollout with IMCAS 2026 momentum

By Pallavi Madhiraju on February 2, 2026   Medical Devices & Diagnostics  

Cynosure Lutronic sets stage for global Mosaic 3D rollout with IMCAS 2026 momentum

Find out how Cynosure Lutronic’s Mosaic 3D laser device could redefine non-ablative resurfacing after CE mark approval under EU MDR.

Recent Posts

  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
  • Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes